

Remicade (Infliximab) Patient Referral and Prescription Sheet

Patient Information									
Patient Name:					Date:	Date:			
DOB:					Height:	Height:		; 🗆 cm	
Allergies:					Weight:	Weight:			
Primary Diagnosis									
Diagnosis		ICD-10	Diagnosis				ICD-10		
Crohn's Disease of small intestine without complications				□ Crohn's Disease of large intestine without complications K50.10				K50.10	
Crohn's Disease, unspecified without complications K50.90				Ulcerative Chronic pancolitis without complications K51.00				K51.00	
Plaque Psoriasis L40.0				Psoriatic PsoriasisL40.52				L40.52	
C Rheumatoid arth		M06.9	Ankylosing Spondylitis M45.9				M45.9		
Ulcerative Colitis	, unspecified with	K51.90	C Other						
Medication Order									
Remicade	Carter Renflexis	🛛 Avsola	Infliximab	Inflectra	Zymfentra		Refills x one year		
Dosing: Initiation: Administer mg/kg IV over at least two hours at weeks 0, 2 and 6 per Maintenance: Administer mg/kg IV over minutes every weeks Round to the nearest 100mg vial size OR exact dose of: mg 120mg SC every 2 weeks Other Nursing Orders Skilled nursing visit for clinical assessment, administration of medication. Initiate plan of tr maintain access device as indicated in Ancillary Orders. Remove peripheral IV or access from					indicated below				
Ancillary Orders									
 Pre-medications: Diphenhydramine: 25mg PO 30 min pre-infusion Acetaminophen: 650mg PO 30 min pre-infusion Famotidine: 20 mg PO x1 dose Other pre-meds:				 IV Flush Orders: Peripheral: NS 1-3 mL before/after use Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw. Heparin (100 unit/mL) 3 to 5 mL final flush CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Heparin (10 units/mL) 3 to 5 mL final flush Refill x one year 					
Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr									
Therapy Specific Documentation					Other Required Documentation				
Please include the following lab results CMP CBC LFTs CRP Infliximab Trough Levels Other				 Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. H & P OR progress note(s) Medication List- Please list past and present DMARDS/biologics below with dates of discontinue, if applicable Hepatitis B Surface Antigen Hepatitis B Core Antibody Total (not Core IgM) QuantiFERON-TB Gold 					
Provider Information									
Provider Name:					Provider Phone:				
Provider NPI:				F	Provider Fax:				
Provider Address:									

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature: _

Date: ____

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.